• Je něco špatně v tomto záznamu ?

An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)

X. Leleu, E. Terpos, RG. Sanz, J. Cooney, P. O'Gorman, J. Minarik, R. Greil, C. Williams, D. Gray, Z. Szabo,

. 2016 ; 91 (8) : 806-11. [pub] 20160608

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031748

Neutropenia is a well-known dose-limiting toxicity associated with lenalidomide plus dexamethasone treatment in patients with multiple myeloma; however, little is known about its management and associated outcomes in the real world setting. The present prospective, multicenter, observational study evaluated the incidence, management, and outcomes of grade 3/4 neutropenia in patients with relapsed or relapsed/refractory multiple myeloma who initiated treatment with lenalidomide plus dexamethasone. Of 198 patients, 62 (31%, 95% CI: 25, 38) experienced grade 3/4 neutropenia, and half of these patients experienced 3 or more events during the 12-month observational period. Grade 3/4 neutropenia occurred throughout lenalidomide treatment, with a median time to first event of 8.8 weeks (Q1, Q3: 5.9, 17.3). In a multivariate analysis, diagnosis of relapsed and refractory disease was associated with grade 3/4 neutropenia. Lenalidomide exposure reduction, use of G-CSF, unplanned hospitalization, and outpatient clinic visits were more common in patients who experienced grade 3/4 neutropenia than in those who did not. In conclusion, grade 3/4 neutropenia is a common toxicity and patients are at continued risk throughout treatment with lenalidomide and dexamethasone. Further efforts should be made to improve the recommendations for neutropenia management in this population. Am. J. Hematol. 91:806-811, 2016. © 2016 Wiley Periodicals, Inc.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031748
003      
CZ-PrNML
005      
20171027120252.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.24416 $2 doi
035    __
$a (PubMed)27169523
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Leleu, Xavier $u Department of Haematology, Hôpital Claude Huriez, Lille, France.
245    13
$a An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM) / $c X. Leleu, E. Terpos, RG. Sanz, J. Cooney, P. O'Gorman, J. Minarik, R. Greil, C. Williams, D. Gray, Z. Szabo,
520    9_
$a Neutropenia is a well-known dose-limiting toxicity associated with lenalidomide plus dexamethasone treatment in patients with multiple myeloma; however, little is known about its management and associated outcomes in the real world setting. The present prospective, multicenter, observational study evaluated the incidence, management, and outcomes of grade 3/4 neutropenia in patients with relapsed or relapsed/refractory multiple myeloma who initiated treatment with lenalidomide plus dexamethasone. Of 198 patients, 62 (31%, 95% CI: 25, 38) experienced grade 3/4 neutropenia, and half of these patients experienced 3 or more events during the 12-month observational period. Grade 3/4 neutropenia occurred throughout lenalidomide treatment, with a median time to first event of 8.8 weeks (Q1, Q3: 5.9, 17.3). In a multivariate analysis, diagnosis of relapsed and refractory disease was associated with grade 3/4 neutropenia. Lenalidomide exposure reduction, use of G-CSF, unplanned hospitalization, and outpatient clinic visits were more common in patients who experienced grade 3/4 neutropenia than in those who did not. In conclusion, grade 3/4 neutropenia is a common toxicity and patients are at continued risk throughout treatment with lenalidomide and dexamethasone. Further efforts should be made to improve the recommendations for neutropenia management in this population. Am. J. Hematol. 91:806-811, 2016. © 2016 Wiley Periodicals, Inc.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a dexamethason $x aplikace a dávkování $7 D003907
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a internacionalita $7 D038622
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x komplikace $x farmakoterapie $7 D009101
650    _2
$a multivariační analýza $7 D015999
650    _2
$a neutropenie $x chemicky indukované $7 D009503
650    _2
$a prospektivní studie $7 D011446
650    _2
$a záchranná terapie $7 D016879
650    _2
$a thalidomid $x aplikace a dávkování $x analogy a deriváty $7 D013792
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Terpos, Evangelos $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
700    1_
$a Sanz, Ramón García $u Department of Hematology, Hospital Universitario De Salamanca, Salamanca, Spain.
700    1_
$a Cooney, Julian $u Department of Hematology, Royal Perth Hospital and University of Western Australia, Crawley, Western Australia, Australia.
700    1_
$a O'Gorman, Peter $u Mater University Hospital, UCD School of Medicine and Medical Science, Dublin, Ireland.
700    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, Medical Faculty of Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Greil, Richard $u IIIrd Medical Department, Paracelsus Medical University Salzburg and Salzburg Cancer Research Institute, Salzburg, Austria.
700    1_
$a Williams, Catherine $u Center for Clinical Hematology, Nottingham University Hospitals, Nottingham, United Kingdom.
700    1_
$a Gray, Diep $u Consultant Biostatistician, Cambridge, United Kingdom.
700    1_
$a Szabo, Zsolt $u Research and Development, Amgen (Europe) GmbH, Zug, Switzerland.
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 91, č. 8 (2016), s. 806-11
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27169523 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171027120337 $b ABA008
999    __
$a ok $b bmc $g 1255341 $s 992775
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 91 $c 8 $d 806-11 $e 20160608 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace